Glenmede Trust’s Oncolytics Biotech ONCY Stock Holding History

Glenmede Trust’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-210	Closed	–	–	3097
2019 Q3	$0	Hold	210	–	–	﹤0.01%	3088
2019 Q2	$0	Hold	210	–	–	﹤0.01%	3142
2019 Q1	$0	Hold	210	–	–	﹤0.01%	3145
2018 Q4	$0	Buy	+210	New	+$569	﹤0.01%	3068

Other funds holding ONCY

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Glenmede Trust's ONCY Position: Q4 2019 in Review

Glenmede Trust sold out of Oncolytics Biotech (ONCY) in Q4 2019, closing a stake of 210 shares.

Glenmede Trust first reported a position in ONCY in Q4 2018 and held it in 4 quarters. The position peaked at $0 in Q3 2019. 28 funds tracked by Wall St. Rank hold ONCY as of Q4 2019.

Glenmede Trust reported no remaining Oncolytics Biotech position as of Q4 2019 after selling out during the quarter.
Glenmede Trust sold 210 Oncolytics Biotech shares in Q4 2019.
Glenmede Trust first reported a position in Oncolytics Biotech in Q4 2018 and held it in 4 quarters.
Glenmede Trust's Oncolytics Biotech position peaked at $0 in Q3 2019.
28 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2019.

Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.